On Thursday, Septerna reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 65 the day before.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While it's not currently an ideal time to jump in, see if the stock manages to form a chart pattern and break out.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
The company holds the No. 143 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
